Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer

NCT06584032 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT06584032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06584032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer
Lead sponsor
Hutchmed
Phase
Phase 3
Overall status
Recruiting
Start date
December 12, 2024
Completion date
June 9, 2029
Enrollment
412 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial cancer